Alx Oncology Holdings (ALXO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.70 (-2.30%), Market cap $0.27B, 52-week low–high $0.41 ~ $2.60.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast ca
Financial statements, price targets, institutional (13F) holdings and related news for Alx Oncology Holdings are updated in real time on BlackAll Trade.
Alx Oncology Holdings trades at $1.70 (-2.30%). Real-time quotes and charts are available on BlackAll Trade.
Alx Oncology Holdings has a market cap of about $0.27B.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD